Advanced Search
Search
  
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire

Markets
Stocks
Sectors
Investing Tools
Overview
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
TRIMERIS (NQ: TRMS)
+0.0500 (+2.174%)
at
2.350
19,394 in Volume
Add to:
My Watchlist
Data as of 08:10 PM EST Feb 9,2010
Quote
Overview
Price and Volume
View Detailed Quote
chart
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
Today's Open 2.420
Bid (Size) 2.370 (500)
Ask (Size) 2.390 (400)
Prev. Close 2.300
Today's Range 2.350 - 2.420
52wk Range 1.010 - 3.680
Shares Outstanding 22,349,841
Morningstar Profile
View Full Profile
TRIMERIS
A biopharmaceutical company, engaged in the commercialization of a class of antiviral drug treatments called fusion inhibitors.
Healthcare
Biotechnology
Exchange Traded NQ
Market Cap 52.52M
Related Companies ATHX HDST BSMD RSOL
Featured News
Read More
Arigene Co., Ltd. Announces Termination of Tender Offer To Purchase and Return of Validly Tendered Shares of Common Stock of Trimeris, Inc.
Dec 29, 2009
from PRNewsWire News Releases
Arigene Co., Ltd. Enters Into Amendment To Merger Agreement With Trimeris, Inc.
Nov 17, 2009
from PRNewsWire News Releases
Featured News
Read More
BeaconEquity.com Issues TraderNotes on Active Stocks: OPSY, WYNN, UCBH, ATML, TRMS, CENX, RSMI, FLWS
Jul 14, 2008
from PRNewsWire News Releases
New Interim Results Demonstrate High Response Rate With FUZEON(R) Plus Darunavir Regardless of Existing Protease Inhibitor Resistance
Jul 20, 2007
from PRNewsWire News Releases
New Trial to Study Investigational Integrase Inhibitor in Combination with FUZEON(R) Once-Daily Dosing Strategy
Jul 17, 2007
from PRNewsWire News Releases
More News
Read More
Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Conference calls info supplied by OpenCompany
Fundamental data supplied by Morningstar
Stock quotes supplied by Telekurs USA